Nicotinic acetylcholine receptor agonists: A potential new class of analgesics

Current Topics in Medicinal Chemistry

Volumn 4, Issue 3, 2004, Pages 369-384

  Decker, Michael W ^a   Rueter, Lynne E ^a   Bitner, R Scott ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM; 2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 (6 CHLORO 3 PYRIDAZINYL) 3,8 DIAZABICYCLO[3.2.1]OCTANE; 3,8 DIAZABICYCLO[3.2.1]OCTANE DERIVATIVE; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; ANABASINE; ANABASINE DERIVATIVE; ANALGESIC AGENT; ANATOXIN A; CHLORISONDAMINE; CYTISINE; DIHYDRO BETA ERYTHROIDINE; EPIBATIDINE; HEXAMETHONIUM; LOBELINE; MECAMYLAMINE; METHYLLYCACONITINE; MORPHINE; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NALOXONE; NICOTINE; NICOTINE DERIVATIVE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; SIB 1663; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ANTINOCICEPTION; ANXIETY DISORDER; BINDING AFFINITY; DEPRESSION; DISEASE ASSOCIATION; DIZZINESS; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENANTIOSELECTIVITY; FEMALE; HUMAN; HYPOTHERMIA; MALE; MOTOR DYSFUNCTION; MOUSE; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PAIN ASSESSMENT; PAIN THRESHOLD; POSTTRAUMATIC STRESS DISORDER; RAT; RESPIRATION DEPRESSION; REVIEW; SEX DIFFERENCE; ANIMAL; ANIMAL MODEL; CHEMISTRY; CLASSIFICATION; DRUG EFFECT; PAIN;

ANALGESICS; ANIMALS; MODELS, ANIMAL; NICOTINIC AGONISTS; PAIN; RECEPTORS, NICOTINIC;

EID: 1642340652     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043451447     Document Type: Review

References (146)

1. Williams, M.; Kowaluk, E. A.; Arneric, S. P. Emerging molecular approaches to pain therapy. J. Med. Chem. 1999, 42, 1481-1500.
2. Flores, C. M. The promise and pitfalls of a nicotinic cholinergic approach to pain management [Review]. Pain 2000, 88, 1-6.
3. Flores, C. M.; Hargreaves, K. M. Neuronal nicotinic receptors: New targets in the treatment of pain. Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities; Wiley-Liss: New York, 1998, pp 359-378.
4. Decker, M. W.; Meyer, M. D. Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics. Biochem. Pharmacol. 1999, 58, 917-923.
5. Decker, M. W.; Meyer, M. D.; Sullivan, J. P. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert. Opin. Investig. Drugs 2001, 10, 1819-1830.
6. Glachjen, M. Chronic pain: treatment barriers and strategies for clinical practice. J. Am. Board Fam. Pract. 2001, 14, 211-218.
7. Passik, S. D.; Weinreb, H. J. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv. Ther. 2000, 17, 70-83.
8. Frölich, J. C. A classification of NSAIDS according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol. Sci. 1997, 18, 30-34.
9. Urban, M. K. COX-2 specific inhibitors offer improved advantages over traditional NSAIDS. Orthopedics 2000, 23 (Suppl. 7), S761-764.
10. Kingery, W. S. A critical review of control clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1997, 73, 123-139.
11. Przewlocki, R.; Przewlocka, B. Opioids in chronic pain. Eur. J. Pharmacol. 2001, 429, 79-91.
12. McQuay, H. Opioids in pain management. Lancet 1999, 353, 2229-2232.
13. Fishbain, D. Evidence-based data on pain relief with antidepressants. Ann. Med. 2000, 32, 305-316.
14. Glauser, J. Tricyclic antidepressant poisoning. Cleve. Clin. J. Med. 2000, 67, 704-719.
15. McQuay, H. J.; Tramèr M.; Mye, B. A.; Carroll, D.; Wiffen, P. J.; Moore, R. A. A systematic review of antidepressants in neuropathic pain. Pain 1996, 68, 217-227.
16. Rose, M. A.; Kam, P. C. A. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002, 57, 451-462.
17. Tremont-Lukas, I. W.; Megeff, C.; Backonja, M.-M. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 2000, 60, 1029-1052.
18. Besson, J. M.; Chaouch, A. Peripheral and spinal mechanisms of nociception. Physiol. Rev. 1987, 67, 67-186.
19. Kharkevich, D. A.; Churukanov, V. V. Pharmacological regulation of descending cortical control of the nociceptive processing. Eur. J. Pharmacol. 1999, 375, 121-131.
20. Milian, M. J. Descending control of pain. Prog. Neurobiol. 2002, 66, 355-474.
21. Millan, M. J. The induction of pain: an integrative review. Prog. Neurobiol. 1999, 57, 1-64.
22. Dennis, S. G.; Melzack, R.; Gutman, S.; Boucher, F. Pain modulation by adrenergic agents and morphine as measured by three pain tests. Life Sci. 1980, 26, 1247-1259.
23. Tjolsen, A.; Berge, O. G.; Hunskaar, S.; Rosland, J. H.; Hole, K. The formalin test: an evaluation of the method. Pain 1992, 51, 5-17.
24. Hargreaves, K.; Dubner, R.; Brown, F.; Flores, C.; Joris, J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32, 77-88.
25. Attal, N.; Bouhassira, D. Mechanisms of pain in peripheral neuropathy. Acta. Neurol. Scand. 1999, 173 (Suppl.), 12-24.
26. Dale, H. H. The action of certain esters and ethers of choline, and their relation to muscarine. J. Pharmacol. Exp. Ther. 1914, 6, 147-190.
27. Fatt, P.; Katz, B. Spontaneous activity at motor nerve endings. J. Physiol. (Lond.) 1952, 117, 109-128.
28. Fertuck, H. C.; Salpeter, M. M. Localization of acetylcholine receptor by 125I-labeled alpha-bungarotoxin binding at mouse motor endplates. Proc. Natl. Acad. Sci. USA 1974, 71, 1376-1378.
29. Sargent, P. B. The diversity of neuronal nicotinic acetylcholine receptors. Ann. Rev. Neurosci. 1993, 16, 403-443.
30. Lukas, R. J.; Changeux, J. P.; Le Novere, N.; Albuquerque, E. X.; Balfour, D. J.; Berg, D. K.; Bertrand, D.; Chiappinelli, V. A.; Clarke, P. B.; Collins, A. C.; Dani, J. A.; Grady, S. R.; Kellar, K. J.; Lindstrom, J. M.; Marks, M. J.; Quik, M.; Taylor, P. W.; Wonnacott, S. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol. Rev. 1999, 51, 397-401.
31. Corringer, P. J.; Le Novere, N.; Changeux, J. P. Nicotinic receptors at the amino acid level. Annu. Rev. Pharmacol. Toxicol, 2000, 40, 431-458.
32. Drisdel, R. C.; Green, W. N. Neuronal alpha-bungarotoxin receptors are alpha7 subunit homomers. J. Neurosci. 2000, 20, 133-139.
33. Seguela, P.; Wadiche, J.; Dineley-Miller, K.; Dani, J. A.; Patrick, J. W. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J. Neurosci. 1993, 13, 596-604.
34. McGehee, D. S.; Role, L. W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu. Rev. Physiol. 1995, 57, 521-546.
35. Flores, C. M.; Rogers, S. W.; Pabreza, L. A.; Wolfe, B. B.; Kellar, K. J. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is upregulated by chronic nicotine treatment. Mol. Pharmacol. 1992, 41, 31-37.
36. Conroy, W. G.; Berg, D. K. Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions. J. Biol. Chem. 1995, 270, 4424-4431.
37. Flores, C. M.; DeCamp, R. M.; Kilo, S.; Rogers, S. W.; Hargreaves, K. M. Neuronal nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion: Demonstration of α3β 4, a novel subtype in the mammalian nervous system. J. Neurosci. 1996, 16, 7892-7901.
38. Changeux, J. P.; Edelstein, S. J. Allosteric receptors after 30 years. Neuron 1998, 21, 959-980.
39. Davis, L.; Pollock, L. J.; Stone, T. Visceral pain. Surg. Gynecol. Obstet. 1932, 55, 418-426.
40. Tripathi, H. L.; Martin, B. R.; Aceto, M. D. Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels. J. Pharmacol. Exp. Ther. 1982, 221, 91-96.
41. Damaj, M. I.; Feiyin, M.; Dukat, M.; Glassco, W.; Glennon, R. A.; Martin, B. R. Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. J. Pharmacol. Exp. Ther. 1998, 284, 1058-1065.
42. Pomerleau, O. F.; Turk, D. C.; Fertig, J. B. The effects of cigarette smoking on pain and anxiety. Addictive Behaviors 1984, 9, 265-271.
43. Pomerleau, O. F. Nicotine as a psychoactive drug: Anxiety and pain reduction. Psychopharmacol. Bull. 1986, 22, 865-869.
44. Fertig, J. B.; Pomerleau, O. F.; Sanders, B. Nicotine-produced antinociception in minimally deprived smokers and ex-smokers. Addictive Behaviors 1986, 11, 239-248.
45. Perkins, K. A.; Grobe, J. E.; Stiller, R. L.; Scierka, A.; Goettler, J.; Reynolds, W.; Jennings, J. R. Effects of nicotine on thermal pain detection in humans. Exp. Clin. Psychopharmacol. 1994, 2, 95-106.
46. Jamner, L. D.; Girdler, S. S.; Shapiro, D.; Jarvik, M. E. Pain inhibition, nicotine, and gender. Exp. Clin. Psychopharmacol. 1998, 6, 96-106.
47. Cepeda-Benito, A.; Reynoso, J.; McDaniel, E. H. Associative tolerance to nicotine analgesia in the rat: tail-flick and hot-plate tests. Exp. Clin. Psychopharmacol. 1998, 6, 248-254.
48. Damaj, M. I.; Welch, S. P.; Martin, B. R. Characterization and modulation of acute tolerance to nicotine in mice. J. Pharmacol. Exp. Ther. 1996, 277, 454-461.
49. Bannon, A. W.; Decker, M. W.; Kim, D. J. B.; Campbell, J. E.; Arneric, S. P. ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain. Brain Res. 1998, 801, 158-163.
50. Damaj, M. I.; Martin, B. R. Tolerance to the antinociceptive effect of epibatidine after acute and chronic administration in mice. Eur. J. Pharmacol. 1996, 300, 51-57.
51. Daly, J. W.; Garraffo, H. M.; Spande, T. F.; Decker, M. W.; Sullivan, J. P.; Williams, M. Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opioid analgesics. Natural Prod. Rep. 2000, 17, 131-135.
52. Sullivan, J. P.; Decker, M. W.; Brioni, J. D.; Donnelly-Roberts, D.; Anderson, D. J.; Bannon, A. W.; Kang, C.; Adams, P.; Piattoni-Kaplan, M.; Buckley, M. J.; Gopalakrishnan, M.; Williams, M.; Arneric, S. P. (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J Pharmacol. Exp. Ther. 1994, 271, 624-631.
53. Sullivan, J. P.; Briggs, C. A.; Donnelly-Roberts, D.; Brioni, J. D.; Radek, R. J.; McKenna, D. G.; Campbell, J. E.; Arneric, S. P.; Decker, M. W.; Bannon, A. W. (±)-Epibatidine can differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChRs). Med. Chem. Res. 1994, 4, 502-516.
54. Badio, B.; Daly, J. W. Epibatidine, a potent analgetic and nicotinic agonist. Mol. Pharmacol. 1994, 45, 563-569.
55. Traynor, J. R. Epibatidine and pain. Br. J. Anaesthesia 1998, 81, 69-76.
56. Damaj, M. I.; Creasy, K. R.; Grove, A. D.; Rosecrans, J. A.; Martin, B. R. Pharmacological effects of epibatidine optical enantiomers. Brain Res. 1994, 664, 34-40.
57. Bannon, A. W.; Gunther, K. L.; Decker, M. W. Is epibatidine really analgesic? Dissociation of the activity, temperature, and analgesic effects of (±)-epibatidine. Pharmacol. Biochem. Behav. 1995, 51, 693-698.
58. Curzon, P.; Nikkel, A. L.; Bannon, A. W.; Arneric, S. P.; Decker, M. W. Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (+/-)-epibatidine in rats. J. Pharmacol. Exp. Ther. 1998, 287, 847-853.
59. Gilbert, S. D.; Clark, T. M.; Flores, C. M. Antihyperalgesic activity of epibatidine in the formalin model of facial pain. Pain 2001, 89, 159-165.
60. Lawand, N. B.; Lu, Y.; Westlund, K. N. Nicotinic cholinergic receptors: potential targets for inflammatory pain relief. Pain 1999, 80, 291-299.
61. Kesingland, A. C.; Gentry, C. T.; Panesar, M. S.; Bowes, M. A.; Vernier, J. M.; Cube, R.; Walker, K.; Urban, L. Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain. Pain 2000, 86, 113-118.
62. Sullivan, J. P.; Donnelly-Roberts, D.; Briggs, C. A.; Anderson, D. J.; Gopalakrishnan, M.; Piattoni-Kaplan, M.; Campbell, J. E.; McKenna, D. G.; Molinari, E.; Hettinger, A. M.; Garvey, D. S.; Wasicak, J. T.; Holladay, M. W.; Williams, M.; Arneric, S. P. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand. Neuropharmacology 1996, 35, 725-734.
63. Bannon, A. W.; Decker, M. W.; Holladay, M. W.; Curzon, P.; Donnelly-Roberts, D.; Puttfarcken, P. S.; Bitner, R. S.; Diaz, A.; Dickenson, A. H.; Porsolt, R. D.; Williams, M.; Arneric, S. P. Broad spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 1998, 279, 77-81.
64. Donnelly-Roberts, D. L.; Puttfarcken, P. S.; Kuntzweiler, T. A.; Briggs, C. A.; Anderson, D. J.; Campbell, J. E.; Piattoni-Kaplan, M.; McKenna, D. G.; Wasicak, J. T.; Holladay, M. W.; Williams, M.; Arneric, S. P. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine] - a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors - I - in vitro characterization. J. Pharmacol, Exp. Ther. 1998, 285, 777-786.
65. Holladay, M. W.; Bai, H.; Li, Y. H.; Lin, N. H.; Daanen, J. F.; Ryther, K. B.; Wasicak, J. T.; Kincaid, J. F.; He, Y.; Hettinger, A. M.; Huang, P.; Anderson, D. J.; Bannon, A. W.; Buckley, M. J.; Campbell, J. E.; Donnelly-Roberts, D. L.; Gunther, K. L.; Kim, D. J. B.; Kuntzweiler, T. A.; Sullivan, J. P.; Decker, M. W.; Arneric, S. P. Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent - effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice. Biorganic Med. Chem. Lett. 1998, 8, 2797-2802.
66. Holladay, M. W.; Wasicak, J. T.; Lin, N. H.; He, Y.; Ryther, K. B.; Bannon, A. W.; Buckley, M. J.; Kim, D. J. B.; Decker, M. W.; Anderson, D. J.; Campbell, J. E.; Kuntzweiler, T. A.; Donnelly-Roberts, D. L.; Piattoni-Kaplan, M.; Briggs, C. A.; Williams, M.; Arneric, S. P. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via reuronal ricotinic acetylcholine receptors. J. Med. Chem. 1998, 41, 407-412.
67. Holladay, M. W.; Decker, M. W. Discovery of ABT-594 and related neuronal nicotinic acetylcholine receptor modulators as analgesic agents: Medicinal chemistry and biology. Adv. Med. Chem. 2000, 5, 85-113.
68. Meyer, M. D.; Decker, M. W.; Rueter, L. E.; Anderson, D. J.; Dart, M. J.; Kim, K. H.; Sullivan, J. P.; Williams, M. The identification of novel structural compound classes exhibiting high affinity for neuronal nicotinic acetylcholine receptors and analgesic efficacy in preclinical models of pain. Eur. J. Pharmacol. 2000, 393, 171-177.
69. Decker, M. W.; Bannon, A. W.; Buckley, M. J.; Kim, D. J. B.; Holladay, M. W.; Ryther, K. B.; Lin, N. H.; Wasicak, J. T.; Williams, M.; Arneric, S. P. Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice. Eur. J. Pharmacol. 1998, 346, 23-33.
70. Bannon, A. W.; Decker, M. W.; Curzon, P.; Buckley, M. J.; Kim, D. J. B.; Radek, R. J.; Lynch, J. K.; Wasicak, J. T.; Lin, N. H.; Arnold, W. H.; Holladay, M. W.; Williams, M.; Arneric, S. P. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine] - a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors. II. in vivo characterization. J. Pharmacol. Exp. Ther. 1998, 285, 787-794.
71. Boyce, S.; Webb, J. K.; Shepheard, S. L.; Russell, M. G. N.; Hill, R. G.; Rupniak, N. M. J. Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats. Pain 2000, 85, 443-450.
72. Barlocco, D.; Cignarella, G.; Tondi, D.; Vianello, P.; Villa, S.; Bartolini, A.; Ghelardini, C.; Galeotti, N.; Anderson, D. J.; Kuntzweiler, T. A.; Colombo, D.; Toma, L. Mono- and disubstituted-3,8-diazabicyclo[3.2.1]octane derivatives as analgesics structurally related to epibatidine - synthesis, activity, and modeling. J. Med. Chem. 1998, 41, 674-681.
73. Ghelardini, C.; Galeotti, N.; Barlocco, D.; Bartolini, A. Antinociceptive profile of the new nicotinic agonist DBO-83. Drug Devel. Res. 1997, 40, 251-258.
74. Vernier, J. M.; Holsenback, H.; Cosford, N. D. P.; Whitten, J. P.; Menzaghi, F.; Reid, R.; Rao, T. S.; Sacaan, A. I.; Lloyd, G. K.; Suto, C. M.; Chavez-Noriega, L. E.; Washburn, M. S.; Urrutia, A.; McDonald, I. A. Con formationally restricted analogs of nicotine and anabasine. Biorganic. Med. Chem. Lett. 1998, 8, 2173-2178.
75. Romanelli, M. N.; Manetti, D.; Scapecchi, S.; Borea, P. A.; Dei, S.; Bartolini, A.; Ghelardini, C.; Gualtieri, F.; Guandalini, L.; Varani, K. Structure-affinity relationships of a unique nicotinic ligand: N-1-dimethyl-N-4-phenylpiperazinium iodide (DMPP). J. Med. Chem. 2001, 44, 3946-3955.
76. Damaj, M. I.; Patrick, G. S.; Creasy, K. R.; Martin, B. R. Pharmacology of lobeline, a nicotinic receptor-ligand. J. Pharmacol. Exp. Ther. 1997, 282, 410-419.
77. Bencherif, M.; Lovette, M. E.; Fowler, K. W.; Arrington, S.; Reeves, L.; Caldwell, W. S.; Lippiello, P. M. RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. J. Pharmacol. Exp. Ther. 1996, 279, 1413-1421.
78. Damaj, M. I.; Glassco, W.; Aceto, M. D.; Martin, B. R. Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist. J. Pharmacol. Exp. Ther. 1999, 291, 390-398.
79. Briggs, C. A.; Anderson, D. J.; Brioni, J. D.; Buccafusco, J. J.; Buckley, M. J.; Campbell, J. E.; Decker, M. W.; Donnelly-Roberts, D.; Elliott, R. L.; Gopalakrishnan, M.; Holladay, M. W.; Hui, Y. H.; Jackson, W. J.; Kim, D. J. B.; Marsh, K. C.; Oneill, A.; Prendergast, M. A.; Ryther, K. B.; Sullivan, J. P.; Arneric, S. P. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav. 1997, 57, 231-241.
80. Meyer, E. M.; Tay, E. T.; Papke, R. L.; Meyers, C.; Huang, G, L.; de Fiebre, C. M. 3-[2,4-dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat α7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res. 1997, 768, 49-56.
81. Decker, M.; Brioni, J.; Bannon, A.; Arneric, S. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci. 1995, 56, 545-570.
82. Sullivan, J. P.; Donnelly-Roberts, D.; Briggs, C. A.; Anderson, D. J.; Gopalakrishnan, M.; Xue, I. C.; Plattoni-Kaplan, M.; Molinari, E.; Campbell, J. E.; McKenna, D. G.; Gunn, D. E.; Lin, N. H.; Ryther, K. B.; He, Y.; Holladay, M. W.; Wonnacott, S.; Williams, M.; Arneric, S. P. ABT-089 [2 - methyl -3 (2 - (S) - pyrrolidinylmethoxy)pyridine]. 1. a potent and selective cholinergic channel modulator with neuroprotective properties. J. Pharmacol. Exp. Ther. 1997, 283, 235-246.
83. Brioni, J. D.; Kim, D. J. B.; O'Neill, A.; Brodie, M. S.; Decker, M. W.; Arneric, S. P. ABT-089 [2-methyl-3(2-(S)-pyrrolidinylmethoxy) pyridine dihydrochloride]: Discriminative stimulus properties and electrophysiological actions. Drug Devel Res. 1997, 40, 259-166.
84. Nanri, M.; Yamamoto, J.; Miyake, H.; Watanabe, H. Protective effect of GTS-21, a novel nicotinic receptor agonist, on delayed neuronal death induced by ischemia in gerbils. Jpn. J. Pharmacol. 1998, 76, 23-29.
85. Chavez-Noriega, L. E.; Crona, J. H.; Washburn, M. S.; Urrutia, A.; Elliott, K. J.; Johnson, E. C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 1997, 280, 346-356.
86. Harvey, S. C.; Maddox, F. N.; Luetje, C. W. Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits. J. Neurochem. 1996, 67, 1953-1959.
87. Clarke, P. B.; Schwartz, R. D.; Paul, S. M.; Pert, C. B.; Pert, A. Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin. J. Neurosci. 1985, 5, 1307-1315.
88. Ward, J. M.; Cockcroft, V. B.; Lunt, G. G.; Smillie, F. S.; Wonnacott, S. Methyllycaconitine: a selective probe for neuronal alpha-bungarotoxin binding sites. FEBS Lett. 1990, 270, 45-48.
89. McIntosh, J. M.; Gardner, S.; Luo, S.; Garrett, J. E.; Yoshikami, D. Conus peptides: novel probes for nicotinic acetylcholine receptor structure and function. Eur. J. Pharmacol. 2000, 393, 205-208.
90. Luo, S.; Kulak, J. M.; Cartier, G. E.; Jacobsen, R. B.; Yoshikami, D.; Olivera, B. M.; McIntosh, J. M. alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release. J. Neurosci. 1998, 18, 8571-8579.
91. Mogg, A. J.; Whiteaker, P.; McIntosh, J. M.; Marks, M.; Collins, A. C.; Wonnacott, S. Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum. J. Pharmacol. Exp. Ther. 2002, 302, 197-204.
92. Collins, A. C.; Evans, C. B.; Miner, L. L.; Marks, M. J. Mecamylamine blockade of nicotine responses: evidence for two brain nicotinic receptors. Pharmacol. Biochem. Behav. 1986, 24, 1767-1773.
93. Glick, S. D.; Greenstein, S. Differential effects of scopolamine and mecamylamine on passive avoidance behavior. Life Sci. 1972, 11, 169-179.
94. Takayama, H.; Majewska, M. D.; London, E. D. Interactions of noncompetitive inhibitors with nicotinic receptors in the rat brain. J. Pharmacol. Exp. Ther. 1989, 251, 1083-1089.
95. Paton, W. D. M.; Zaimis, E. J. The methonium compounds. Pharmacol. Rev. 1952, 4, 219-253.
96. Clarke, P. B. Chronic central nicotinic blockade after a single administration of the bisquaternary ganglion-blocking drug chlorisondamine. Br. J. Pharmacol. 1984, 83, 527-535.
97. Gillberg, P. G.; Hartvig, P.; Gordh, T.; Sottile, A.; Jansson, I.; Archer, T.; Post, C. Behavioral effects after intrathecal administration of cholinergic receptor agonists in the rat. Psychopharmacol. 1990, 100, 464-469.
98. Khan, I. M.; Buerkle, H.; Taylor, P.; Yaksh, T. L. Nociceptive and antinociceptive responses to intrathecally administered nicotinic agonists. Neuropharmacology 1998, 37, 1515-1525.
99. Rueter, L. E.; Meyer, M. D.; Decker, M. W. Spinal mechanisms underlying A-85380-induced effects on acute thermal pain. Brain Res. 2000, 872, 93-101.
100. Khan, I. M.; Stanislaus, S.; Zhang, L.; Taylor, P.; Yaksh, T. L. A-85380 and epibatidine each interact with disparate spinal nicotinic receptor subtypes to achieve analgesia and nociception. J Pharmacol. Exp. Ther. 2001, 297, 230-239.
101. Iwamoto, E. T. Antinociception after nicotine administration into the mesopontine tegmentum of rats: Evidence for muscarinic actions. J. Pharmacol. Exp. Ther. 1989, 251, 412-421.
102. Bitner, R. S.; Nikkel, A. L.; Bannon, A. W.; Arneric, S. P.; Decker, M.W. Supraspinal C-fos induction produced by a novel cholinergic channel modulator analgesic, ABT-594. Soc. Neurosci. Abst. 1997, 23, 1200.
103. Bitner, R. S.; Nikkel, A. L.; Curzon, P.; Arneric, S. P.; Bannon, A. W.; Decker, M. W. Role of the nucleus raphe magnus in antinociception produced by ABT-594 - Immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons. J. Neurosci. 1998, 18, 5426-5432.
104. Iwamoto, E. T. Characterization of the antinociception induced by nicotine in the pedunculopontine tegmental nucleus and the nucleus raphe magnus. J. Pharmacol. Exp. Ther. 1991, 120-133.
105. Lindstrom, J.; Anand, R.; Peng, X.; Gerzanich, V.; Wang, F.; Li, Y. Neuronal nicotinic receptor subtypes. Ann. NY Acad. Sci. 1995, 757, 100-116.
106. Wada, E.; Wada, K.; Boulter, J.; Deneris, E.; Heinemann, S.; Patrick, J.; Swanson, L. W. Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J. Comp. Neurol. 1989, 284, 314-335.
107. Decker, M. W.; Curzon, P.; Holladay, M. W.; Nikkel, A. L.; Bitner, R. S.; Bannon, A. W.; Donnelly-Roberts, D. L.; Puttfarcken, P. S.; Kuntzweiler, T. A.; Briggs, C. A.; Williams, M.; Americ, S. P. The role of neuronal nicotinic acetylcholine receptors in antinociception: Effects of ABT-594. J. Physiol. 1998, 92, 221-224.
108. Bitner, R. S.; Nikkel, A. L.; Curzon, P.; Donnelly-Roberts, D. L.; Puttfarcken, P. S.; Namovic, M.; Jacobs, I. C.; Meyer, M. D.; Decker, M. W. Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat. Brain Res. 2000, 871, 66-74.
109. Wang, Q. P.; Nakai, Y. The dorsal raphe: an important nucleus in pain modulation. Brain Res. Bull. 1994, 34, 575-585.
110. Marubio, L. M.; Arroyo-Jimenez, M. D.; Cordero-Erausquin, M.; Lena, C.; Le Novere, N.; d'Exaerde, A. D.; Huchet, M.; Damaj, M. I.; Changeux, J. P. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 1999, 398, 805-810.
111. Plenge, P.; Mellerup, E. T.; Wortwein, G. Characterization of epibatidine binding to medial habenula: potential role in analgesia. J. Pharmacol. Exp. Ther. 2002, 302, 759-765.
112. Whiteaker, P.; Peterson, C. G.; Xu, W.; McIntosh, J. M.; Paylor, R.; Beaudet, A. L.; Collins, A. C.; Marks, M. J. Involvement of the alpha3 subunit in central nicotinic binding populations. J. Neurosci. 2002, 22, 2522-2529.
113. Rao, T. S.; Correa, L. D.; Reid, R. T.; Lloyd, G. K. Evaluation of anti-nociceptive effects of neuronal nicotinic acetylcholine receptor (nAChR) ligands in the rat tail-flick assay. Neuropharmacology 1996, 35, 393-405.
114. Damaj, M. I.; Meyer, E. M.; Martin, B. R. The antinociceptive effects of alpha 7 nicotinic agonists in an acute pain model. Neuropharmacology 2000, 39, 2785-2791.
115. Knott, V. J.; De Lugt, D. Subjective and brain-evoked responses to electrical pain stimulation: effects of cigarette smoking and warning condition. Pharmacol. Biochem. Behav. 1991, 39, 889-893.
116. Pauli, P.; Rau, H.; Zhuang, P.; Brody, S.; Birbaumer, N. Effects of smoking on thermal pain threshold in deprived and minimally-deprived habitual smokers. Psychopharmacol. 1993, 111, 472-476.
117. Wewers, M. E.; Dhatt, R. K.; Snively, T. A.; Tejwani, G. A. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkelphalin levels in rats. Brain Res 1999, 822, 107-113.
118. Damaj, M. I. Influence of gender and sex hormones on nicotine acute pharmacological effects in mice. J. Pharmacol. Exp. Ther. 2001, 296, 132-140.
119. Carstens, E.; Anderson, K. A.; Simons, C. T.; Carstens, M. I.; Jinks, S. L. Analgesia induced by chronic nicotine infusion in rats - Differences by gender and pain test. Psychopharmacol. 2001, 157, 40-45.
120. Lavand'homme, P. M.; Eisenach, J. C. Sex differences in cholinergic analgesia II: Differing mechanisms in two models of allodynia. Anesthesiology 1999, 91, 1455-1461.
121. Craft, R. M.; Milholland, R. B. Sex differences in cocaine- and nicotine-induced antinociception in the rat. Brain Res. 1998, 809, 137-140.
122. Chiari, A.; Tobin, J. R.; Pan, H.-L. M. D.; Hood, D. D.; Eisenach, J. C. Sex differences in cholinergic analgesia I: A supplemental nicotinic mechanism in normal females. Anesthesiology 1999, 91, 1447-1454.
123. Rouff, G. E. Depression in the patient with chronic pain. J. Family Practice 1996, 43, S25-33.
124. Sharp, T. J.; Harvey, A. G. Chronic pain and posttraumatic stress disorder: mutual maintenance? Clin. Psychol. Rev. 2001, 21, 857-877.
125. Verma, S.; Gallagher, R. M. The psychopharmacologic treatment of depression and anxiety in the context of chronic pain. Curr. Pain Headache Reports 2002, 6, 30-39.
126. Fishbain, D. A.; Goldberg, M.; Rosomoff, R. S.; Rosomoff, H. Completed suicide in chronic pain. Clin. J. Pain. 1991, 7, 29-36.
127. McBeth, J.; Silman, A. J. The role of psychiatric disorders in fibromyalgia. Curr. Rheumatol. Reports 2001, 3, 157-164.
128. Covey, L. S.; Glassman, A. H.; Stetner, F. Cigarette smoking and major depression. J. Addict Dis. 1998, 17, 35-46.
129. Salin-Pascual, R. J.; de la Fuente, J. R.; Galicia-Polo, L.; Drucker-Colin, R. Effects of transdermal nicotine on mood and sleep in nonsmoking major depressed patients. Psychopharmacol. 1995, 121, 476-479.
130. Salin-Pascual, R. J.; Rosas, M.; Jimenez-Genchi, A.; Rivera-Meza, B. L.; Delgado-Parra, V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J. Clin. Psychiatry 1996, 57, 387-389.
131. Kuch, K. Psychological factors and the development of chronic pain. Clin. J. Pain 2001, 17 (suppl. 14), S33-38.
132. Piccitto, M. R.; Brunzell, D. H.; Calderone, B. J. Effect of nicotine and nicotinic receptors on anxiety and depression. NeuroReport 2002, 13, 1097-1106.
133. Xu, W.; Gelber, S.; Orr-Urtreger, A.; Armstrong, D.; Lewis, R. A.; Ou, C. N.; Patrick, J.; Role, L.; De Biasi, M.; Beaudet, A. L. Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor. Proc. Natl. Acad. Sci. USA 1999, 96, 5746-5751.
134. Xu, W.; Orr-Urtreger, A.; Nigro, F.; Gelber, S.; Sutcliffe, C. B.; Armstrong, D.; Patrick, J. W.; Role, L. W.; Beaudet, A. L.; De Biasi, M. Multiorgan autonomic dysfunction in mice lacking the beta2 and the beta4 subunits of neuronal nicotinic acetylcholine receptors. J. Neurosci. 1999, 19, 9298-9305.
135. Rau, H.; Schweizer, R.; Zhuang, P.; Pauli, P.; Brody, S.; Larbig, W.; Heinle, H.; Muller, M.; Elbert, T.; Dworkin, B. Cigarette smoking, blood lipids, and baroreceptor-modulated nociception. Psychopharmacol. 1993, 110, 337-341.
136. Leikola-Pelho, T.; Jackson, D. M. Preferential stimulation of locomotor activity by ventral tegmental microinjections of (-)-nicotine. Pharmacol. Toxicol. 1992, 70, 50-52.
137. Clarke, P. B.; Kumar, R. The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br. J. Pharmacol. 1983, 78, 329-337.
138. Beleslin, D. B.; Krstic, S. K. Further studies on nicotine-induced emesis: nicotinic mediation in area postrema. Physiol. Behav. 1987, 39, 681-686.
139. Damaj, M. I.; Glassco, W.; Dukat, M.; Martin, B. R. Pharmacological characterization of nicotine-induced seizures in mice. J. Pharmacol. Exp. Ther. 1999, 291, 1284-1291.
140. le Novere, N.; Zoli, M.; Lena, C.; Ferrari, R.; Picciotto, M. R.; Merlo-Pich, E.; Changeux, J. P. Involvement of alpha6 nicotinic receptor subunit in nicotine-elicited locomotion, demonstrated by in vivo antisense oligonucleotide infusion. Neuroreport 1999, 10, 2497-2501.
141. Picciotto, M. R.; Zoli, M.; Rimondini, R.; Lena, C.; Marubio, L. M.; Pich, E. M.; Fuxe, K.; Changeux, J. P. Acetylcholine-receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 1998, 391, 173-177.
142. Benowitz, N. L. Pharmacology of nicotine: addiction and therapeutics. Annu. Rev. Pharmacol. Toxicol. 1996, 36, 597-613.
143. Slade, J.; Henningfield, J. E. Tobacco product regulation: context and issues. Food and Drug Law J. 1998, 53, 43-74.
144. Pickworth, W. B.; Bunker, E. B.; Henningfield, J. E. Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacol. 1994, 115, 9-14.
145. 3H]epibatidine binding in response to repeated nicotine administration in rats. Psychopharmacol. 2000, 150, 1-8.
146. McCallum, S. E.; Caggiula, A. R.; Epstein, L. H.; Saylor, S.; Ploskina, T.; Sved, A. F. Mecamylamine blocks the development of tolerance to nicotine in rats: implications for the mechanisms of tolerance. Psychopharmacol. 1999, 141, 332-338.